Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 134

Results For "RI"

11184 News Found

Europe (AGES, Austria) inspects Shilpa Biologicals’ Dharwad site
Drug Approval | May 06, 2025

Europe (AGES, Austria) inspects Shilpa Biologicals’ Dharwad site

he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice


Briefs: Tatva Chintan Pharma Chem and Shelter Pharma
News | May 06, 2025

Briefs: Tatva Chintan Pharma Chem and Shelter Pharma

Tatva Chintan Pharma Chem receives export order worth $35, 55,000


AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Clinical Trials | May 03, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease


Strides acquires identified ANDAs from Nostrum Laboratories, USA
News | May 03, 2025

Strides acquires identified ANDAs from Nostrum Laboratories, USA

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs


Neuland Laboratories completes USFDA inspection at Unit 2
Drug Approval | May 03, 2025

Neuland Laboratories completes USFDA inspection at Unit 2

The FDA issued Form 483 with one observation related to building and facility management


Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
Drug Approval | May 01, 2025

Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules

Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base


Sigachi Industries signs MoU with Respilon Group
News | May 01, 2025

Sigachi Industries signs MoU with Respilon Group

This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.


USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility
Drug Approval | May 01, 2025

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

The Subsidiary has received one inspectional observation in Form 483


Briefs: Alembic Pharmaceuticals  and Bafna Pharmaceuticals
News | May 01, 2025

Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals

Alembic Pharmaceuticals commissions new facility at Pithampur


Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
Biopharma | April 28, 2025

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide